Garetosmab

Drug Profile

Garetosmab

Alternative Names: REGN2477

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Activin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibrodysplasia ossificans progressiva
  • Phase I Musculoskeletal disorders

Most Recent Events

  • 15 Nov 2017 Phase-II clinical trials in Fibrodysplasia ossificans progressiva in United Kingdom (IV) (NCT03188666)
  • 03 Aug 2017 Garetosmab receives Fast track status from the US FDA for Fibrodysplasia ossificans progressiva in second quarter of 2017
  • 19 Jun 2017 Regeneron Pharmaceuticals plans the LUMINA-1 phase II trial for Fibrodysplasia ossificans progressiva (NCT03188666)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top